GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Kolon TissueGene Inc (XKRX:950160) » Definitions » Beneish M-Score

Kolon TissueGene (XKRX:950160) Beneish M-Score : -0.71 (As of Mar. 02, 2025)


View and export this data going back to 2017. Start your Free Trial

What is Kolon TissueGene Beneish M-Score?

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Warning Sign:

Beneish M-Score -0.71 higher than -1.78, which implies that the company might have manipulated its financial results.

The historical rank and industry rank for Kolon TissueGene's Beneish M-Score or its related term are showing as below:

XKRX:950160' s Beneish M-Score Range Over the Past 10 Years
Min: -5.71   Med: -0.76   Max: 12.85
Current: -0.71

During the past 8 years, the highest Beneish M-Score of Kolon TissueGene was 12.85. The lowest was -5.71. And the median was -0.76.


Kolon TissueGene Beneish M-Score Historical Data

The historical data trend for Kolon TissueGene's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Kolon TissueGene Beneish M-Score Chart

Kolon TissueGene Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Beneish M-Score
Get a 7-Day Free Trial -0.01 -3.76 2.42 -0.29 4.21

Kolon TissueGene Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4.02 4.21 5.86 0.86 -0.71

Competitive Comparison of Kolon TissueGene's Beneish M-Score

For the Biotechnology subindustry, Kolon TissueGene's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Kolon TissueGene's Beneish M-Score Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Kolon TissueGene's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where Kolon TissueGene's Beneish M-Score falls into.



Kolon TissueGene Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of Kolon TissueGene for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 0.7525+0.528 * 5.5623+0.404 * 1.467+0.892 * 0.7204+0.115 * 1.624
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 1.6458+4.679 * -0.029965-0.327 * 1.5108
=-0.71

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Sep24) TTM:Last Year (Sep23) TTM:
Total Receivables was ₩596 Mil.
Revenue was 2098.277 + 958.81 + 1212.676 + 772.203 = ₩5,042 Mil.
Gross Profit was 207.756 + 99.878 + 160.039 + 70.556 = ₩538 Mil.
Total Current Assets was ₩32,201 Mil.
Total Assets was ₩192,873 Mil.
Property, Plant and Equipment(Net PPE) was ₩6,075 Mil.
Depreciation, Depletion and Amortization(DDA) was ₩770 Mil.
Selling, General, & Admin. Expense(SGA) was ₩10,753 Mil.
Total Current Liabilities was ₩39,022 Mil.
Long-Term Debt & Capital Lease Obligation was ₩4,978 Mil.
Net Income was -5861.125 + -5276.465 + -3783.214 + -3894.336 = ₩-18,815 Mil.
Non Operating Income was 0 + 0 + 0 + 0 = ₩0 Mil.
Cash Flow from Operations was -4941.759 + -5760.325 + -5109.741 + 2776.04 = ₩-13,036 Mil.
Total Receivables was ₩1,100 Mil.
Revenue was 1750.7 + 661.441 + 509.108 + 4077.889 = ₩6,999 Mil.
Gross Profit was 186.947 + 74.93 + 78.934 + 3815.085 = ₩4,156 Mil.
Total Current Assets was ₩58,637 Mil.
Total Assets was ₩146,233 Mil.
Property, Plant and Equipment(Net PPE) was ₩7,694 Mil.
Depreciation, Depletion and Amortization(DDA) was ₩1,720 Mil.
Selling, General, & Admin. Expense(SGA) was ₩9,070 Mil.
Total Current Liabilities was ₩16,031 Mil.
Long-Term Debt & Capital Lease Obligation was ₩6,051 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(596.264 / 5041.966) / (1099.888 / 6999.138)
=0.11826 / 0.157146
=0.7525

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(4155.896 / 6999.138) / (538.229 / 5041.966)
=0.593773 / 0.10675
=5.5623

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (32201.09 + 6075.455) / 192872.644) / (1 - (58637.067 + 7694.484) / 146233.256)
=0.801545 / 0.546399
=1.467

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=5041.966 / 6999.138
=0.7204

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(1719.682 / (1719.682 + 7694.484)) / (769.978 / (769.978 + 6075.455))
=0.18267 / 0.112481
=1.624

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(10753.396 / 5041.966) / (9069.902 / 6999.138)
=2.132778 / 1.29586
=1.6458

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((4978.423 + 39022.218) / 192872.644) / ((6051.167 + 16030.961) / 146233.256)
=0.228133 / 0.151006
=1.5108

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(-18815.14 - 0 - -13035.785) / 192872.644
=-0.029965

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Kolon TissueGene has a M-score of -0.71 signals that the company is likely to be a manipulator.


Kolon TissueGene Beneish M-Score Related Terms

Thank you for viewing the detailed overview of Kolon TissueGene's Beneish M-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


Kolon TissueGene Business Description

Traded in Other Exchanges
N/A
Address
9713 Key West Avenue, Suite 300, Rockville, MD, USA, 20850
Kolon TissueGene Inc is a biopharmaceutical company that develops regenerative therapies for the treatment of various orthopedic disorders. It is developing four product candidates, TG-C, TG-B, TG-D and TG-N for regeneration of cartilage, bone, disc and nerve.

Kolon TissueGene Headlines

No Headlines